[A19-98] Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 02.03.2020

Project no.:
A19-98

Commission:
Commission awarded on 29.11.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication/Intervention:

Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer if prior adjuvant trastuzumab-based therapy was completed less than one year ago

Result of dossier assessment:

An advantage in the outcome "recurrence" is accompanied by major disadvantages in side effects during the treatment phase; added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Project no. Title Status
A20-40 Neratinib (breast cancer) - Addendum to Commission A19-98 Commission completed

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.